{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-284839","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2021-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.673338+00:00","generated_at":"2026-06-29T00:55:32.702564+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Altimmune Phase 1 pemvidutide shows 10.3% mean weight loss at 1.8 mg; NASH IND cleared","bullets":["Mean weight loss of 10.3% at 1.8 mg dose vs. 1.6% placebo; 100% of subjects lost ≥5%.","No discontinuations due to adverse events; side effects mild-to-moderate, no dose titration needed.","FDA cleared IND for NASH; 12-week NAFLD liver fat trial to start soon.","Phase 2 obesity trial (48-week) planned for H1 2022; diabetes trial expected Q4 2021.","Favorable trends in blood pressure, lipids, HOMA-IR; ketone bodies rise supports glucagon mechanism."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-284839","json":"https://secwatch.observer/filing/0001193125-21-284839.json","markdown":"https://secwatch.observer/filing/0001193125-21-284839.md","text":"https://secwatch.observer/filing/0001193125-21-284839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000119312521284839/0001193125-21-284839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000119312521284839/d200964d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:55:32.702564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}